Clinical causes of inflammation in peritoneal dialysis patients

International Journal of Nephrology

Volumn 2014, Issue , 2014, Pages

  Cho, Yeoungjee ^a,b   Hawley, Carmel M ^a,b   Johnson, David W ^a,b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901783809     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2014/909373     Document Type: Review

References (93)

1. Blake P. G., Integrated end-stage renal disease care: the role of peritoneal dialysis. Nephrology Dialysis Transplantation 2001 16 supplement 5 61 66 2-s2.0-0034874295 (Pubitemid 32750432)
2. McDonald S. P., Marshall M. R., Johnson D. W., Polkinghorne K. R., Relationship between dialysis modality and mortality. Journal of the American Society of Nephrology 2009 20 1 155 163 2-s2.0-58149523217 10.1681/ASN. 2007111188
3. Davies S. J., Van Biesen W., Nicholas J., Lameire N., Integrated care. Peritoneal Dialysis International 2001 21 supplement 3 S269 S274 2-s2.0-0035568834 (Pubitemid 34406816)
4. Bargman J. M., Thorpe K. E., Churchill D. N., Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. Journal of the American Society of Nephrology 2001 12 10 2158 2162 2-s2.0-0034823268 (Pubitemid 32880353)
5. Johnson D. W., Dent H., Hawley C. M., McDonald S. P., Rosman J. B., Brown F. G., Bannister K., Wiggins K. J., Association of dialysis modality and cardiovascular mortality in incident dialysis patients. Clinical Journal of the American Society of Nephrology 2009 4 10 1620 1628 2-s2.0-73349104627 10.2215/CJN.01750309
6. System, U.S.R.D, USRDS, 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2013 Bethesda, Md, USA National Institutes of Health, National Institue of Diabetes and Digestive and Kidney Diseases
7. Tonelli M., Wiebe N., Culleton B., House A., Rabbat C., Fok M., McAlister F., Garg A. X., Chronic kidney disease and mortality risk: a systematic review. Journal of the American Society of Nephrology 2006 17 7 2034 2047 2-s2.0-33745852282 10.1681/ASN.2005101085 (Pubitemid 44036188)
8. Foley R. N., Parfrey P. S., Sarnak M. J., Clinical epidemiology of cardiovascular disease in chronic renal disease. American Journal of Kidney Diseases 1998 32 5, supplement 3 S112 S119 2-s2.0-0031733696 (Pubitemid 28527268)
9. Paniagua R., Amato D., Vonesh E., Correa-Rotter R., Ramos A., Moran J., Mujais S., Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. Journal of the American Society of Nephrology 2002 13 5 1307 1320 2-s2.0-0036236303 (Pubitemid 34441412)
10. Becker A. E., De Boer O. J., Van der Wal A. C., The role of inflammation and infection in coronary artery disease. Annual Review of Medicine 2001 52 289 297 2-s2.0-0035123913 10.1146/annurev.med.52.1.289 (Pubitemid 32195326)
11. Pecoits-Filho R., Heimbürger O., Bárány P., Suliman M., Fehrman-Ekholm I., Lindholm B., Stenvinkel P., Associations between circulating inflammatory markers and residual renal function in CRF patients. American Journal of Kidney Diseases 2003 41 6 1212 1218 2-s2.0-0038100467 10.1016/S0272-6386(03)00353-6 (Pubitemid 36637976)
12. Sharain K., Hoppensteadt D., Bansal V., Singh A., Fareed J., Progressive increase of inflammatory biomarkers in chronic kidney disease and end-stage renal disease. Clinical and Applied Thrombosis/Hemostasis 2013 19 3 303 308
13. Zoccali C., Tripepi G., Mallamaci F., Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? Journal of the American Society of Nephrology 2006 17 12, supplement 3 S169 S173 2-s2.0-33845268461 10.1681/ASN.2006080910 (Pubitemid 44865244)
14. Carrero J. J., Axelsson J., Avesani C. M., Heimbürger O., Lindholm B., Stenvinkel P., Being an inflamed peritoneal dialysis patient-a Dante's journey. Contributions to Nephrology 2006 150 144 151 2-s2.0-33745231689 10.1159/000093514 (Pubitemid 44155344)
15. Chung S. H., Heimbürger O., Stenvinkel P., Bergström J., Lindholm B., Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrology Dialysis Transplantation 2001 16 11 2240 2245 2-s2.0-0035159862 (Pubitemid 33062151)
16. Cordeiro A. C., Carrero J. J., Abensur H., Lindholm B., Stenvinkel P., Systemic and local inflammation in peritoneal dialysis: mechanisms, biomarkers and effects on outcome. Contributions to Nephrology 2009 163 132 139 2-s2.0-67651215897 10.1159/000223791
17. García-López E., Carrero J. J., Suliman M. E., Lindholm B., Stenvinkel P., Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Peritoneal Dialysis International 2007 27 supplement 2 S205 S209 2-s2.0-35748937374 (Pubitemid 350047702)
18. Pecoits-Filho R., Stenvinkel P., Yee-Moon Wang A., Heimbürger O., Lindholm B., Chronic inflammation in peritoneal dialysis: the search for the holy grail? Peritoneal Dialysis International 2004 24 4 327 339 2-s2.0-4444236544 (Pubitemid 39206627)
19. Stenvinkel P., Chung S. H., Heimbürger O., Lindholm B., Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. Peritoneal Dialysis International 2001 21 supplement 3 S157 S162 2-s2.0-0035568843 (Pubitemid 34406796)
20. Black S., Kushner I., Samols D., C-reactive protein. The Journal of Biological Chemistry 2004 279 47 48487 48490 2-s2.0-10344239447 10.1074/jbc.R400025200 (Pubitemid 39625721)
21. Hurst S. M., Wilkinson T. S., McLoughlin R. M., Jones S., Horiuchi S., Yamamoto N., Rose-John S., Fuller G. M., Topley N., Jones S. A., IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001 14 6 705 714 2-s2.0-0034960582 10.1016/S1074-7613(01)00151-0 (Pubitemid 32592418)
22. Bertin D., Stephan D., Khrestchatisky M., Desplat-Jégo S., Is TWEAK a biomarker for autoimmune/chronic inflammatory diseases? Frontiers in Immunology 2013 4, article 489 10.3389/fimmu.2013.00489
23. Burkly L. C., Michaelson J. S., Hahm K., Jakubowski A., Zheng T. S., TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007 40 1 1 16 2-s2.0-36049022442 10.1016/j.cyto.2007.09.007 (Pubitemid 350088500)
24. Lambie M., Chess J., Donovan K. L., Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. Journal of the American Society of Nephrology 2013 24 2071 2080
25. Wang A. Y.-M., Consequences of chronic inflammation in peritoneal dialysis. Seminars in Nephrology 2011 31 2 159 171 2-s2.0-79952778908 10.1016/j.semnephrol.2011.01.005
26. Wang A. Y.-M., Prognostic value of C-reactive protein for heart disease in dialysis patients. Current Opinion in Investigational Drugs 2005 6 9 879 886 2-s2.0-24644434976 (Pubitemid 41269367)
27. Pecoits-Filho R., Carvalho M. J., Stenvinkel P., Lindholm B., Heimbürger O., Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Peritoneal Dialysis International 2006 26 1 53 63 2-s2.0-33745513606 (Pubitemid 44339662)
28. Cho Y., Johnson D. W., Vesey D. A., Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. BMC Nephrology 2014 15, article 8
29. Cho Y., Johnson D. W., Vesey D. A., Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patients. Peritoneal Dialysis International 2014 10.3747/pdi.2013.00272
30. Borazan A., Ustün H., Ustundag Y., Aydemir S., Bayraktaroglu T., Sert M., Yilmaz A., The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels. Mediators of Inflammation 2004 13 3 201 204 2-s2.0-4143106955 10.1080/09511920410001713493 (Pubitemid 39093343)
31. Chung S. H., Heimbürger O., Stenvinkel P., Bergström J., Lindholm B., Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrology Dialysis Transplantation 2001 16 11 2240 2245 2-s2.0-0035159862 (Pubitemid 33062151)
32. Descamps-Latscha B., Herbelin A., Nguyen A. T., Roux-Lombard P., Zingraff J., Moynot A., Verger C., Dahmane D., De Groote D., Jungers P., Dayer J.-M., Balance between IL-1 β TNF- α and their specific inhibitors in chronic renal failure and maintenance dialysis: relationships with activation markers of T cells, B cells, and monocytes. Journal of Immunology 1995 154 2 882 892 2-s2.0-0028983572
33. Poole S., Bird T. A., Selkirk S., Gaines-Das R. E., Choudry Y., Stephenson S. L., John Kenny A., Saklatvaa J., Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine 1990 2 6 416 422 2-s2.0-0025519112
34. Bemelmans M. H. A., Gouma D. J., Buurman W. A., Influence of nephrectomy on tumor necrosis factor clearance in a murine model. Journal of Immunology 1993 150 5 2007 2017 2-s2.0-0027245985 (Pubitemid 23129679)
35. Shimizu H., Bolati D., Adijiang A., Muteliefu G., Enomoto A., Nishijima F., Dateki M., Niwa T., NF- b plays an important role in indoxyl sulfate-induced cellular senescence, fibrotic gene expression, and inhibition of proliferation in proximal tubular cells. American Journal of Physiology-Cell Physiology 2011 301 5 C1201 C1212 2-s2.0-80054884869 10.1152/ajpcell.00471.2010
36. Watanabe H., Miyamoto Y., Honda D., p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney International 2013 83 4 582 592
37. Rossi M., Campbell K. L., Johnson D. W., Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease. Archives of Medical Research 2014 10.1016/j.arcmed.2014.04.002
38. Williams J. D., Craig K. J., Topley N., Von Ruhland C., Fallon M., Newman G. R., Mackenzie R. K., Williams G. T., Morphologic changes in the peritoneal membrane of patients with renal disease. Journal of the American Society of Nephrology 2002 13 2 470 479 2-s2.0-0036158071 (Pubitemid 34106290)
39. Catalan M. P., Santamaría B., Reyero A., Ortiz A., Egido J., Ortiz A., 3,4-Di-deoxyglucosone-3-ene promotes leukocyte apoptosis. Kidney International 2005 68 3 1303 1311 2-s2.0-30944457299 10.1111/j.1523-1755.2005. 00528.x (Pubitemid 43246451)
40. Topley N., Mackenzie R., Petersen M. M., Beavis M. J., Williams D., Thomas Faict N. D., Peluso F., Coles G. A., Davies M., Williams J. D., In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid. Nephrology Dialysis Transplantation 1991 6 8 574 581 2-s2.0-0025776459
41. Witowski J., Topley N., Jorres A., Liberek T., Coles G. A., Williams J. D., Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney International 1995 47 1 282 293 2-s2.0-0028950696
42. Davies S. J., Bryan J., Phillips L., Russell G. I., Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrology Dialysis Transplantation 1996 11 3 498 506 2-s2.0-0030012242 (Pubitemid 26092790)
43. Davies S. J., Phillips L., Russell G. I., Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Nephrology Dialysis Transplantation 1998 13 4 962 968 2-s2.0-0031924486 10.1093/ndt/13.4.962 (Pubitemid 28161772)
44. Rumpsfeld M., McDonald S. P., Johnson D. W., Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. Journal of the American Society of Nephrology 2006 17 1 271 278 2-s2.0-33645457575 10.1681/ASN.2005050566
45. Fried L., Higher membrane permeability predicts poorer patient survival. Peritoneal Dialysis International 1997 17 4 387 389 2-s2.0-0030732163 (Pubitemid 27470215)
46. Cho J. H., Hur I. K., Kim C. D., Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study. Nephrology, Dialysis, Transplantation 2010 25 6 1964 1973 10.1093/ndt/gfp767
47. Witowski J., Jörres A., Coles G. A., Williams J. D., Topley N., Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA. Kidney International 1996 50 4 1212 1223 2-s2.0-0029848801 (Pubitemid 26342812)
48. Kim S., Oh K. H., Oh J., Biocompatible peritoneal dialysis solution preserves residual renal function. American Journal of Nephrology 2012 36 4 305 316
49. Ayuzawa N., Ishibashi Y., Takazawa Y., Kume H., Fujita T., Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan. Peritoneal Dialysis International 2012 32 2 159 167 2-s2.0-84857893776 10.3747/pdi.2010.00234
50. Passlick-Deetjen J., Lage C., Lactate-buffered and bicarbonate-buffered solutions with less glucose degradation products in a two-chamber system. Peritoneal Dialysis International 2000 20 supplement 2 S42 S47 2-s2.0-0034044155 (Pubitemid 30410555)
51. Mortier S., De Vriese A. S., Lameire N., Recent concepts in the molecular biology of the peritoneal membrane-implications for more biocompatible dialysis solutions. Blood Purification 2003 21 1 14 23 2-s2.0-0037261185 10.1159/000067867 (Pubitemid 36173343)
52. Mortier S., De Vriese A. S., McLoughlin R. M., Topley N., Schaub T. P., Passlick-Deetjen J., Lameire N. H., Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. Journal of the American Society of Nephrology 2003 14 5 1296 1306 2-s2.0-0037407760 10.1097/01.ASN.0000060681.91079.30 (Pubitemid 36514669)
53. Devuyst O., Topley N., Williams J. D., Morphological and functional changes in the dialysed peritoneal cavity: impact of more biocompatible solutions. Nephrology Dialysis Transplantation 2002 17 supplement 3 12 15 2-s2.0-0036242468 (Pubitemid 34450111)
54. Mackenzie R., Holmes C. J., Jones S., Williams J. D., Topley N., Clinical indices of in vivo biocompatibility: the role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients. Kidney International, Supplement 2003 64 88 S84 S93 2-s2.0-0344011072 (Pubitemid 37452817)
55. Mortier S., Faict D., Lameire N. H., De Vriese A. S., Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney International 2005 67 4 1559 1565 2-s2.0-16244382350 10.1111/j.1523-1755.2005.00237.x (Pubitemid 40463136)
56. Mortier S., Faict D., Schalkwijk C. G., Lameire N. H., De Vriese A. S., Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney International 2004 66 3 1257 1265 2-s2.0-4344696765 10.1111/j.1523-1755.2004.00879.x (Pubitemid 39121036)
57. Kim S., Oh J., Kim S., Chung W., Ahn C., Kim S. G., Oh K.-H., Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrology Dialysis Transplantation 2009 24 9 2899 2908 2-s2.0-69249088031 10.1093/ndt/gfp054
58. Weiss L., Stegmayr B., Malmsten G., Tejde M., Hadimeri H., Siegert C. E., Ahlmén J., Larsson R., Ingman B., Simonsen O., van Hamersvelt H. W., Johansson A. C., Hylander B., Mayr M., Nilsson P.-H., Andersson P. O., De los Ríos T., Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Peritoneal Dialysis International 2009 29 6 647 655 2-s2.0-77954337529
59. Lai K. N., Lam M. F., Leung J. C., A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products. Peritoneal Dialysis International 2012 32 3 280 291 10.3747/pdi.2010.00176
60. Cooker L. A., Luneburg P., Holmes C. J., Jones S., Topley N., O'Donoghue D., Frenken I., Brown E., Walls J., Pedersen F. B. I., Freese P., Gokal R., Junor B., Maiorca R., Weiss L., Farrington K., Kristiensen J., Ahlmén J., Struijk D., Brouwer R., Ryckelynck J. P., Williams J. D., Hopwood A. M., Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Peritoneal Dialysis International 2001 21 supplement 3 S102 S107 2-s2.0-16744362363 (Pubitemid 34406786)
61. Justo P., Sanz A. B., Egido J., Ortiz A., 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005 54 8 2424 2429 2-s2.0-23644433184 10.2337/diabetes.54.8.2424 (Pubitemid 41134271)
62. Szeto C.-C., Chow K.-M., Lam C. W.-K., Leung C.-B., Kwan B. C.-H., Chung K.-Y., Law M.-C., Li P. K.-T., Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial. Nephrology Dialysis Transplantation 2007 22 2 552 559 2-s2.0-33846654231 10.1093/ndt/gfl559 (Pubitemid 46189901)
63. Lui S. L., Yung S., Yim A., A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. American Journal of Kidney Diseases 2012 60 6 966 975
64. Flessner M. F., Credit K., Henderson K., Vanpelt H. M., Potter R., He Z., Henegar J., Robert B., Peritoneal changes after exposure to sterile solutions by catheter. Journal of the American Society of Nephrology 2007 18 8 2294 2302 2-s2.0-34547646301 10.1681/ASN.2006121417 (Pubitemid 47203845)
65. Zakaria E. R., Matheson P. J., Hurt R. T., Garrison R. N., Chronic infusion of sterile peritoneal dialysis solution abrogates enhanced peritoneal gene expression responses to chronic peritoneal catheter presence. Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis 2008 24 7 15 2-s2.0-58149229701
66. Dasgupta M. K., Larabie M., Biofilms in peritoneal dialysis. Peritoneal Dialysis International 2001 21 supplement 3 S213 S217 2-s2.0-0035571673 (Pubitemid 34406807)
67. Gorman S. P., Adair C. G., Mawhinney W. M., Incidence and nature of peritoneal catheter biofilm determined by electron and confocal laser scanning microscopy. Epidemiology and Infection 1994 112 3 551 559 2-s2.0-0028303685 (Pubitemid 24183340)
68. Read R. R., Eberwein P., Dasgupta M. K., Grant S. K., Lam K., Nickel J. C., Costerton J. W., Peritonitis in peritoneal dialysis: bacterial colonization by biofilm spread along the catheter surface. Kidney International 1989 35 2 614 621 2-s2.0-0024496909 (Pubitemid 19051761)
69. Flessner M. F., Credit K., Richardson K., Potter R., Li X., He Z., Hoskins G., Henegar J., Peritoneal inflammation after twenty-week exposure to dialysis solution: effect of solution versus catheter-foreign body reaction. Peritoneal Dialysis International 2010 30 3 284 293 2-s2.0-77957686145 10.3747/pdi.2009.00100
70. Fiedler R., Schneider I., Fischer K., Deuber H. J., Osten B., Is interleukin-6 concentration in the dialysate of continuous ambulatory peritoneal dialysis patients a prognostic parameter in peritonitis? Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis 2001 17 159 162 2-s2.0-0035236286
71. Lai K. N., Lai K. B., Lam C. W. K., Chan T. M., Li F. K., Leung J. C. K., Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. American Journal of Kidney Diseases 2000 35 4 644 652 2-s2.0-0034110753 (Pubitemid 30185509)
72. Zalunardo N. Y., Rose C. L., Ma I. W. Y., Altmann P., Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis. Kidney International 2007 71 7 687 692 2-s2.0-33947655993 10.1038/sj.ki.5002127 (Pubitemid 46494567)
73. Troidle L., Kliger A., Gorban-Brennan N., Finkelstein F., Course of C-reactive protein during continuous peritoneal dialysis-associated peritonitis. Nephrology 2005 10 5 442 445 2-s2.0-28444482029 10.1111/j.1440-1797.2005.00442. x (Pubitemid 41727266)
74. Brown F., Chapter 6: Peritoneal Dialysis. ANZDATA 2012 Annual Report-35th edition, 2012, http://www.anzdata.org.au/anzdata/AnzdataReport/35thReport/ 2012c06-peritoneal-v3.pdf
75. Boudville N., Kemp A., Clayton P., Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. Journal of the American Society of Nephrology 2012 23 8 1398 1405 10.1681/ASN.2011121135
76. Troidle L., Finkelstein F., Treatment and outcome of CPD-associated peritonitis. Annals of Clinical Microbiology and Antimicrobials 2006 5, article 6 2-s2.0-33646251376 10.1186/1476-0711-5-6
77. Piraino B., Bernardini J., Brown E., Figueiredo A., Johnson D. W., Lye W.-C., Price V., Ramalakshmi S., Szeto C.-C., ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Peritoneal Dialysis International 2011 31 6 614 630 2-s2.0-84856166505 10.3747/pdi.2011. 00057
78. Yung S., Chan T. M., Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells. Mediators of Inflammation 2012 2012 21 484167 10.1155/2012/484167
79. Strippoli G. F. M., Tong A., Johnson D., Schena F. P., Craig J. C., Catheter-related interventions to prevent peritonitis in peritoneal dialysis: a systematic review of randomized, controlled trials. Journal of the American Society of Nephrology 2004 15 10 2735 2746 2-s2.0-16644370441 10.1097/01.ASN.0000141463.95561.79 (Pubitemid 41103381)
80. Li P. K. T., Szeto C. C., Law M. C., Comparison of double-bag and Y-set disconnect systems in continuous ambulatory peritoneal dialysis: a randomized prospective multicenter study. American Journal of Kidney Diseases 1999 33 3 535 540 2-s2.0-0033011956 (Pubitemid 29107031)
81. Gadallah M. F., Ramdeen G., Mignone J., Patel D., Mitchell L., Tatro S., Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters. American Journal of Kidney Diseases 2000 36 5 1014 1019 2-s2.0-0033759746
82. Wikdahl A. M., Engman U., Stegmayr B. G., Sörenssen J. G., One-dose cefuroxime i.v. and i.p. reduces microbial growth in PD patients after catheter insertion. Nephrology Dialysis Transplantation 1997 12 1 157 160 2-s2.0-0031032626 10.1093/ndt/12.1.157 (Pubitemid 27046220)
83. Krack A., Sharma R., Figulla H. R., Anker S. D., The importance of the gastrointestinal system in the pathogenesis of heart failure. European Heart Journal 2005 26 22 2368 2374 2-s2.0-27644438235 10.1093/eurheartj/ehi389 (Pubitemid 41552965)
84. Magnusson M., Magnusson K.-E., Sundqvist T., Denneberg T., Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 1991 32 7 754 759 2-s2.0-0025899472
85. Simenhoff M. L., Saukkonen J. J., Burke F., Bacterial populations of the small intestine in uremia. Nephron 1978 22 1-3 63 68 2-s2.0-0018114903 (Pubitemid 9051804)
86. Li M., Specian R. D., Berg R. D., Deitch E. A., Effects of protein malnutrition and endotoxin on the intestinal mucosal barrier to the translocation of indigenous flora in mice. Journal of Parenteral and Enteral Nutrition 1989 13 6 572 578 2-s2.0-0024355459 (Pubitemid 20005552)
87. Goncalves S., Pecoits-Filho R., Perreto S., Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrology, Dialysis, Transplantation 2006 21 10 2788 2794 (Pubitemid 44542232)
88. McIntyre C. W., Harrison L. E., Eldehni M. T., Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clinical Journal of the American Society of Nephrology 2011 6 1 133 141
89. El-Koraie A. F., Naga Y. S., Saaran A. M., Farahat N. G., Hazzah W. A., Endotoxins and inflammation in hemodialysis patients. Hemodialysis International 2013 17 3 359 365
90. Szeto C.-C., Kwan B. C.-H., Chow K.-M., Lai K.-B., Chung K.-Y., Leung C.-B., Li P. K.-T., Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clinical Journal of the American Society of Nephrology 2008 3 2 431 436 2-s2.0-42549129835 10.2215/CJN.03600807
91. Cueto-Manzano A. M., Angel-Zúñiga J. R., Ornelas-Carrillo G., Rojas-Campos E., Martínez-Ramírez H. R., Cortés- Sanabria L., Anti-inflammatory interventions in end-stage kidney disease: a randomized, double-blinded, controlled and crossover clinical trial on the use of pravastatin in continuous ambulatory peritoneal dialysis. Archives of Medical Research 2013 44 8 633 637
92. Purwanto B., Prasetyo D. H., Effect of oral N-acetylcysteine treatment on immune system in continuous ambulatory peritoneal dialysis patients. Acta Medica Indonesiana 2012 44 2 140 144
93. Siribamrungwong M., Yothasamutr K., Puangpanngam K., Periodontal treatment reduces chronic systemic inflammation in peritoneal dialysis patients. Therapeutic Apheresis and Dialysis 2013 10.1111/1744-9987.12105